SCHEMBL23177887

SCHEMBL23177887

CCCCCCC(C)(CCCC)CN[C@](C)(CO)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
MAPT P10636 1/20 0.35
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CES2 O00748 4/20 0.34
HAO1 Q9UJM8 1/20 0.34
CES1 P23141 3/20 0.33
GGPS1 O95749 1/20 0.33
PPARG P37231 6/20 0.32
PPARD Q03181 6/20 0.32
PPARA Q07869 6/20 0.32
HDAC11 Q96DB2 5/20 0.32
TSHR P16473 4/20 0.32
GPR84 Q9NQS5 4/20 0.32
ALDH1A1 P00352 2/20 0.32
TLR2 O60603 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
FABP4 P15090 2/20 0.32
PTPN1 P18031 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23052825 0.98 MEN1 (0.36) MEN1KMT2AMAPTATML3MBTL1
SCHEMBL24476511 0.78 NAALAD2 (0.33)
SCHEMBL9829066 0.76 EPHX1 (0.41) TSHRALDH1A1ALOX15
SCHEMBL20781421 0.75 MEN1 (0.46) MEN1KMT2AMAPTATML3MBTL1
SCHEMBL20781401 0.73 MEN1 (0.41) MEN1KMT2AMAPTATML3MBTL1
SCHEMBL21712880 0.73 MEN1 (0.47) MEN1KMT2AMAPTATML3MBTL1
SCHEMBL20047648 0.72 GPR84 (0.44) MEN1KMT2APPARGPPARDPPARA
SCHEMBL21451430 0.72 NAALAD2 (0.36) TSHRALDH1A1
SCHEMBL21451342 0.72 NAALAD2 (0.36) TSHRALDH1A1
SCHEMBL24926910 0.71 EPHX1 (0.42) MEN1KMT2AMAPTATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11578054-B2 Compounds useful as immunomodulators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-02-14 US disclosed
US-20210094932-A1 COMPOUNDS USEFUL AS IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2021-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210094932-A1 COMPOUNDS USEFUL AS IMMUNOMODULATORS CD74, HLA-DRB1, CD47 MEN1 1857/4885KMT2A 4121/4885MAPT 4038/4885
US-11578054-B2 Compounds useful as immunomodulators CD74, HLA-DRB1, CD47 MEN1 1857/4885KMT2A 4121/4885MAPT 4038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.